Published on 20 Mar 2024 on Motley Fool via Yahoo Finance
Some events are so pivotal for a company that they cause everything to change. The company's world instantly becomes brighter -- or darker.
Madrigal Pharmaceuticals (NASDAQ: MDGL) just experienced such an event. Last Thursday, the company won U.S. Food and Drug (FDA) approval for the first drug targeting the multibillion-dollar market for nonalcoholic steatohepatitis (NASH). Is Madrigal stock now a screaming buy?